| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 04/24/2026 | ±2.0% | +1.7% | over-priced |
| 01/23/2026 | ±1.8% | +0.1% | over-priced |
| 10/24/2025 | ±1.4% | +0.2% | over-priced |
| 04/24/2025 | ±3.0% | -3.7% | under-priced |
| 01/22/2025 | ±1.1% | +1.9% | under-priced |
| 10/18/2024 | ±1.3% | -0.6% | over-priced |
| 04/19/2024 | ±0.9% | +0.5% | over-priced |
| 01/23/2024 | ±1.4% | +4.1% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q4 FY2026 | $1.26 | $21.2B | $3.1B |
| Q3 FY2026 | $1.63 | $21.2B | $4.0B |
| Q2 FY2026 | $1.78 | $22.2B | $4.3B |
| Q1 FY2026 | $1.95 | $22.4B | $4.8B |
Procter & Gamble Company (PG) reports in 39 days, with the next report estimated for 10/21/2026. Across the last 8 reports, options priced an average ±1.6% earnings move while the stock actually moved 1.6% on average — the market has been roughly fair on PG's earnings risk. Fundamentals into the print: EPS down 18.2% year-over-year, revenue up 7.2%. QuantLogix's live 5-factor engine currently reads PG as a buy at 58/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →